
    
      This is a Phase II open-label, multi-center conversion study in stable, adult kidney
      transplant recipients to assess the pharmacokinetics, safety and effectiveness of tacrolimus
      in stable kidney transplant patients converted from a PrografÂ® based immunosuppression
      regimen to a modified release tacrolimus based immunosuppression regimen.
    
  